Sentence examples for involved in malignancy from inspiring English sources

Many key proteins involved in malignancy are translationally controlled, including the potent angiogenic factors VEGF and FGF-2, the oncogenes cyclin D1 and c-myc, the antiapoptotic proteins of the Bcl family, as well as the inhibitor of apoptosis protein survivin (refs. 30, 31; see ref. 1 for a more extensive list of translationally controlled proteins involved in malignancy).

It contains 5 genes (table 8) that are not obviously involved in malignancy and some (e.g. PARP12) are poorly known but all are more or less strongly expressed in CD33 myeloid cells.

HIF-1α was reported to induce c-Myc and VEGFC, which are involved in malignancy (Yoo et al., 2011; Zampell et al., 2012).

Many downstream signaling effectors involved in malignancy are regulated by both Stat3 and NF-κB, such that targeting both of these signaling pathways at once by combining ATRA + AUR, may produce a synergistic tumor suppressive effect.

Elevated eIF4E function in tumours preferentially and disproportionately influences the expression of potent regulators of cell growth and survival proteins that are involved in malignancy and is thereby an attractive new anticancer therapeutic target.

Interacting with other adhesion molecules, Ezrin plays an essential part in the development of tumors, by promoting the proliferation and infiltration of tumor cells, metastasis, neovascularisation, and other biological mechanisms involved in malignancy [ 5- 10].

These modified siRNAs, by mimicking gene structure, enhance siRNA delivery into cells and consequently lead to a better inhibition of genes involved in malignancies.

This has opened a new area of research since first, other factors involved in DNA demethylation may exist and second, several αKG dependent enzymes, such as jumonji histone demethylases [ 75] are epigenetic regulators; therefore, some of these proteins could also be involved in malignancies.

Inspired by the close correlation between FXYD3/FXYD5 and tumor progression (Kayed et al., 2006; Sato et al., 2003; Widegren et al., 2009), we supposed that FXYD6 may be also involved in tumor malignancy.

Our data further demonstrated that Oct-4 expression in LC-CD133+ is involved in tumor malignancy of lung cancers and exhibits refractory properties for chemoradiotherapy in cancer stem-like cells.

Among these, several have been previously shown to be involved in breast malignancy.